Insider trading

Period: 120 months Stock: LLY + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

415 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

415 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

415 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

415 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
415 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
415 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

415 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
4 Sep 2018
Zakrowski Donald A Chief Accounting Officer
Sold, plan not stated
$63.34K 600 at 105.57
14.5%
30 Aug 2018
Sold, plan not stated
$20.03M 190,000 at 105.42
0.2%
20 Aug 2018
Sold, plan not stated
$20.65M 195,000 at 105.89
0.2%
16 Aug 2018
Sold, plan not stated
$20.90M 200,000 at 104.50
0.2%
15 Aug 2018
Sold, plan not stated
$15.67M 151,793 at 103.23
0.1%
10 Aug 2018
Sold, plan not stated
$369.68K 3,587 at 103.06
0.0%
7 Aug 2018
Sold, plan not stated
$2.54M 24,620 at 103.22
0.0%
6 Aug 2018
Sold, plan not stated
$19.92M 195,000 at 102.15
0.2%
2 Aug 2018
Sold, plan not stated 2×
$18.92M 190,000 at 99.58
0.2%
31 Jul 2018
Sold, plan not stated 2×
$20.24M 205,000 at 98.74
0.2%
26 Jul 2018
TAI JACKSON P Director
Bought
$206.44K 2,168 at 95.22
4.2%
First buy on file
25 Jul 2018
Sold, plan not stated 4×
$18.00M 190,000 at 94.73
0.2%
24 Jul 2018
Sold, plan not stated 4×
$17.03M 185,000 at 92.03
0.2%
6 Jul 2018
Sold, plan not stated
$15.74M 180,000 at 87.44
0.1%
5 Jul 2018
Sold, plan not stated
$14.73M 170,000 at 86.62
0.1%
15 Jun 2018
Sold, plan not stated
$15.60M 180,000 at 86.65
0.1%
14 Jun 2018
Sold, plan not stated
$9.30M 107,698 at 86.31
0.1%
14 Jun 2018
Skovronsky Daniel SVP, CSO, and Pres. LRL
Bought
$862.20K 10,000 at 86.22
22.1%
First buy on file
13 Jun 2018
Sold, plan not stated
$957.95K 11,104 at 86.27
0.0%
11 Jun 2018
Sold, plan not stated
$4.42M 51,198 at 86.38
0.0%
4 Jun 2018
Sold, plan not stated
$11.53M 135,478 at 85.13
0.1%
1 Jun 2018
Sold, plan not stated
$3.37M 39,522 at 85.31
0.0%
31 May 2018
Conterno Enrique A SVP&Pres, LillyDiab & LillyUSA
Sold, plan not stated
$2.13M 25,000 at 85.00
16.7%
30 May 2018
Sold, plan not stated
$15.09M 180,000 at 83.85
0.1%
29 May 2018
Shaw Christi SVP and Pres., Lilly Bio-Meds
Sold, plan not stated
$691.77K 8,426 at 82.10
100%
Sold half or more
11 May 2018
Sold, plan not stated
$11.48M 140,000 at 81.97
0.1%
3 May 2018
Simmons Jeffrey N SVP&Pres. Elanco Animal Health
Sold, plan not stated
$708.62K 9,027 at 78.50
6.2%
25 Apr 2018
Sold, plan not stated 2×
$14.55M 180,000 at 80.85
0.1%
16 Apr 2018
Mahony Susan SVP & Pres., Lilly Oncology
Sold, plan not stated
$1.39M 17,379 at 80.08
38.1%
13 Apr 2018
Mahony Susan SVP & Pres., Lilly Oncology
Sold, plan not stated
$413.92K 5,165 at 80.14
10.2%
16 Mar 2018
Smiley Joshua L SVP and CFO
Sold, plan not stated
$237.60K 3,000 at 79.20
13.0%
1 Mar 2018
Zakrowski Donald A Chief Accounting Officer · indirect
Sold, plan not stated
$65.79K 860 at 76.50
34.4%
21 Feb 2018
Zakrowski Donald A Chief Accounting Officer · indirect
Sold, plan not stated
$67.93K 876 at 77.55
26.2%
5 Feb 2018
Simmons Jeffrey N SVP&Pres. Elanco Animal Health
Sold, plan not stated
$780.78K 9,625 at 81.12
6.7%
5 Feb 2018
Zakrowski Donald A Chief Accounting Officer
Sold, plan not stated
$72.98K 900 at 81.09
17.9%
13 Dec 2017
Sold, plan not stated 2×
$17.64M 200,000 at 88.20
0.2%
11 Dec 2017
Simmons Jeffrey N SVP&Pres. Elanco Animal Health
Sold, plan not stated
$1.08M 12,500 at 86.46
9.1%
4 Dec 2017
Mahony Susan SVP & Pres., Lilly Oncology
Sold, plan not stated
$3.15M 36,585 at 86.18
40.0%
4 Dec 2017
Zulueta Alfonso G SVP & President, Lilly Int'l
Sold, plan not stated
$303.75K 3,532 at 86.00
8.1%
10 Nov 2017
Zulueta Alfonso G SVP & President, Lilly Int'l
Sold, plan not stated
$167.59K 2,003 at 83.67
4.4%
4 Oct 2017
Sold, plan not stated
$17.80M 205,000 at 86.81
0.2%
29 Sep 2017
Sold, plan not stated 2×
$16.60M 195,000 at 85.14
0.2%
15 Sep 2017
Sold, plan not stated 2×
$15.68M 190,000 at 82.53
0.2%
31 Aug 2017
Sold, plan not stated
$14.59M 180,000 at 81.06
0.1%
31 Jul 2017
Sold, plan not stated 2×
$18.28M 220,000 at 83.09
0.2%
22 Jun 2017
Sold, plan not stated
$17.73M 210,000 at 84.43
0.2%
20 Jun 2017
Sold, plan not stated
$17.86M 215,000 at 83.05
0.2%
12 Jun 2017
Barnes Melissa S Chief Eth/Cmpl Ofcr & SVP, ERM
Sold, plan not stated
$153.48K 1,900 at 80.78
11.9%
9 Jun 2017
Harrington Michael J Senior VP and General Counsel
Sold, plan not stated
$1.83M 22,833 at 79.97
26.9%
4 May 2017
Conterno Enrique A SVP&Pres, LillyDiab & LillyUSA
Sold, plan not stated
$2.07M 25,000 at 82.76
18.0%
Showing 351–400 of 415. ← Newer Page 8 of 9 Older →